Table of Contents Author Guidelines Submit a Manuscript
Schizophrenia Research and Treatment
Volume 2011, Article ID 596898, 6 pages
Research Article

Second Generation Antipsychotics Improve Sexual Dysfunction in Schizophrenia: A Randomised Controlled Trial

1Mental Health and Neurodegeneration Research Group, The University of Manchester, Manchester M13 9PL, UK
2National Drug Evidence Centre (NDEC), School of Community Based Medicine, The University of Manchester, Manchester M15 6SZ, UK

Received 5 November 2009; Revised 24 August 2010; Accepted 4 November 2010

Academic Editor: D. Naber

Copyright © 2011 Ahmed Mahmoud et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The impact of antipsychotic drug treatment on sexual function was investigated during a randomised trial comparing first generation antipsychotics (FGAs) to (nonclozapine) second generation antipsychotics (SGAs). Sexual function and quality of life were (rater-blind) assessed in 42 patients with DSM-IV schizophrenia (aged 18–65) using the self-report version of the Derogatis Interview for Sexual Function (DISF-SR) and the Heinrichs Quality of Life Scale (QLS), prior to, and 12 weeks following, a change in medication from an FGA drug to either an FGA or SGA drug. SGAs significantly improved sexual function compared to FGAs. Change in sexual function was associated with change in quality of life. Where impaired sexual functioning is a distressing adverse effect of treatment with an FGA agent, consideration should be given to switching to an SGA.